Cancer diagnostics are moving beyond broad screening and into precision-led detection, and EDX Medical founder and chief scientific officer Sir Chris Evans believes the company is positioned at the centre of that transition.
Speaking to DirectorsTalks Interviews on the day EDX Medical’s shares were admitted to AIM, Sir Chris explains why the business is focusing on high-accuracy, clinically validated testing, how partnerships are accelerating commercial traction, and where he sees the biggest gaps in modern healthcare diagnostics.
Read more here or watch the interview below.
Key Moments
00:16 – EDX Medical lands on AIM
01:05 – Taking ultra-accurate tests into the home
02:14 – Sir Chris Evans’ biotech track record
03:21 – The $10bn Verona Pharma win
04:18 – The big names backing EDX
06:05 – Scotland’s prostate testing push
07:16 – 25,000 men, major data set
08:23 – Finding cancer before symptoms
09:15 – Predicting what MRI will show
11:04 – Bowel cancer test launch plans
12:18 – Ovarian, lung and breast next
13:25 – From R&D to commercial sales
14:10 – Why home diagnostics matter
14:52 – Evans’ next big biotech bet
